IP Library Granted Patent US 8,318,210
Granted Patent B2
US 8,318,210 · App. 11/068,124 · Granted Nov 27, 2012

Compositions and methods of making sustained release liquid formulations

Assignee: Neos Therapeutics, LP
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,210
App. No.
11/068,124
Granted
Nov 27, 2012
Kind
B2
Abstract

The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.

Claims (40)

1. A method for preparing a liquid, controlled-release formulation comprising the steps of:

obtaining one or more controlled release microbeads comprising one or more active agents in coated drug-resin complexes;

preparing a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads, wherein the dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation; and

mixing the microbeads and the thixotropic solutions under conditions that minimize the introduction of bubbles in the liquid, wherein said method prepares a shelf-stable, liquid controlled-release formulation having a uniform appearance with no visible lumps.

2. The method of claim 1 , wherein the one or more microbeads comprise one or more of the following: an enteric coat, a resin coat, a lacquer coat, a pH-sensitive coating, a biodegradable polymer matrix, a water soluble matrix, an ionic matrix, combinations and mixtures thereof.

3. The method of claim 1 , wherein the one or more microbeads comprise one or more polymers selected from the group consisting of cellulose, ethylcellulose, methylcellulose, propylcellulose, methoxypropylcellulose, cellulose nitrate, poly(vinyl alcohol), poly(vinyl chloride), polystyrene, polyethylene, polypropylene, poly(ethylene-co-vinyl acetate), poly(hydroxybutyric acid), poly(hydroxyvalerianic acid-co-hydroxybutyric acid), poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), poly(ε-caprolactones), poly(ε-caprolactone-co-DL-lactic acid), poly(maleic anhydride), polyamides, gelatin, chitosan, collagen, poly(hydroxyalkyl)-L-glutamines, poly(γ-ethyl-L-glutaminate-co-glutamic acid), poly(L-leucine-co-L-aspartic acid), poly(proline-co-glutamic acid), poly(alkyl 2-cyanoacrylates), polyurethanes, poly(methyl methacrylate), poly(methyl methacrylate-co-methacrylic acid) and poly(methacrylate-co-hydroxypropyl methacrylate), polystirex, salts, combinations and mixtures thereof.

4. The method of claim 1 , wherein reduced bubble formation comprises the step of using a diaphragm pump to combine the water and the thixotropic agent and one or more preservatives, colorants and flavorants.

5. The method of claim 1 , wherein reduced bubble formation comprises the step of placing the recirculating tube below the surface of the liquid.

6. The method of claim 1 , wherein reduced bubble formation comprises the step of adding liquids along the side of a vessel holding the liquid.

7. The method of claim 1 , wherein reduced bubble formation comprises the step of sprinkling the beads onto the surface of the liquid.

8. The method of claim 1 , wherein reduced bubble formation comprises the step of mixing the solution in the absence of one or more paddles that scrape the vessel.

9. The method of claim 1 , wherein reduced bubble formation comprises the step of using a diaphragm pump to combine one or more of the water, the thixotropic agent, the one or more preservatives, colorants and flavorants.

10. The method of claim 1 , wherein reduced bubble formation comprises the steps of:

placing a recirculating tube below the surface of the liquid;

adding liquids along the side of a vessel holding the liquid; and

using a mixer that lacks scraping paddles.

11. The method of claim 1 , wherein reduced bubble formation comprises the step of mixing the solution with a propeller mixer.

12. The method of claim 1 , wherein reduced bubble formation comprises the step of mixing the solution with a propeller mixer at a speed that reduces cavitation.

13. The method of claim 1 , wherein reduced bubble formation comprises the step of mixing the solution with a propeller that minimizes cavitation.

14. The method of claim 1 , wherein a portion of the one or more beads comprises an immediate release profile and another portion comprise a delayed release profile.

15. The method of claim 1 , wherein the formulation further comprises one or more flavorants, one or more surfactants, one or more dissolved active agents, one or more buffers, one or more excipients, and mixtures and combinations thereof.

16. The method of claim 1 , wherein the one or more active agents are pharmaceutical agents.

17. The method of claim 1 , wherein the one or more active agents comprise vitamins, minerals, nutritional supplements, herbal extracts, gums, gels, oils, salts, mixtures and combinations thereof.

18. The method of claim 1 , wherein the one or more active agents are pharmaceutical agents selected from protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, interferon, receptor, antigen, allergen, antibody, antiviral, antifungal, antihelminthic, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, explosive, pesticide, chemical warfare agent, biowarfare agent, biohazardous agent, infectious agent, prion, radioisotope, vitamin, heterocyclic aromatic compound, carcinogen, mutagen, narcotic, amphetamine, barbiturate, hallucinogen, combinations and mixtures thereof.

19. The method of claim 1 , wherein the one or more active agents comprise a pharmaceutical agent, an enzyme, a cytokine, a growth promoting agent, an antibody, an antigen, a hormone, a vaccine, a cell, a live-attenuated pathogen, a heat-killed pathogen, a virus, a bacteria, a fungi, a peptide, a carbohydrate, a nucleic acid, a lipid, mixtures and combinations thereof.

20. The method of claim 1 , wherein the one or more active agents is selected from wherein the one or more agents may be steroids, respiratory agents, sympathomimetics, local anesthetics, antimicrobial agents, antiviral agents, antifungal agents, antihelminthic agents, insecticides, antihypertensive agents, antihypertensive diuretics, cardiotonics, coronary vasodilators, vasoconstrictors, β-blockers, antiarrhythmic agents, calcium antagonists, anti-convulsants, agents for dizziness, tranquilizers, antipsychotics, muscle relaxants, drugs for Parkinson's disease, respiratory agents, hormones, non-steroidal hormones, antihormones, vitamins, antitumor agents, miotics, herb medicines, antimuscarinic, interfereons, immunokines, cytokines, muscarinic cholinergic blocking agents, mydriatics, psychic energizers, humoral agents, antispasmodics, antidepressant drugs, anti-diabetics, anorectic drugs, anti-allergenics, decongestants, expectorants, antipyretics, antimigrane, anti-malarials, anti-ulcerative, peptides, anti-estrogen, anti-hormone agents, antiulcer agents, anesthetic agent, drugs having an action on the central nervous system, protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, interferon, receptor, antigen, allergen, antibody, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, explosive, pesticide, chemical warfare agent, biowarfare agent, biohazardous agent, infectious agent, prion, radioisotope, vitamin, heterocyclic aromatic compound, carcinogen, mutagen, narcotic, amphetamine, barbiturate, hallucinogen, and vaccines against virus, bacterium, fungi, helminth, cancer, Salmonella, Streptococcus, Brucella, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia , spore, mold, yeast, algae, amoebae, dinoflagellate, unicellular organism, pathogen, combinations and mixtures thereof.

21. The method of claim 1 , wherein the one or more active agents comprises Pseudoephedrine, salts thereof or mixtures of salts thereof.

22. The method of claim 1 , wherein the one or more active agents comprises an antihistamine.

23. The method of claim 1 , wherein the one or more active agents comprises Chlorpheniramine, salts thereof or mixtures of salts thereof.

24. The method of claim 1 , wherein the one or more active agents comprises Dextromethorphan, salts thereof or mixtures of salts thereof.

25. The method of claim 1 , wherein the one or more active agents comprises an analgesic.

26. The method of claim 1 , wherein the one or more active agents comprises an antitussive.

27. The method of claim 1 , wherein the one or more active agents comprises a narcotic.

28. The method of claim 1 , wherein the one or more active agents are disposed on a polystirex bead.

29. The method of claim 1 , wherein the one or more active agents are disposed on a polypropylene bead.

30. The method of claim 1 , wherein the one or more active agents are disposed on a polyethylene bead.

31. The method of claim 1 , wherein the one or more active agents are disposed on a polacrilex bead.

32. The method of claim 1 , wherein the one or more active agents are disposed on a poly-lactic acid (PLA), poly-glycolic acid (PGA) and/or poly-lactic polyglycolic acid (PGLA) bead.

33. A method for preparing a liquid, controlled-release formulation comprising the step of blending one or more controlled release beads comprising one or more active agents in coated drug-resin complexes with a dense, thixotropic solution with a density that is at or about the density of the one or more beads, wherein the dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives under conditions that minimize air bubbles which cling to said beads, wherein said method prepares a shelf-stable, liquid controlled-release formulation having a uniform appearance with no visible lumps.

34. The method for preparing a liquid, controlled-release formulation of claim 33 , comprising the step of blending a mixture comprising one or more controlled-release beads comprising one or more active agents in coated drug-resin complexes, a thickening agent and a surfactant by mixing with a low cavitation propeller and recirculating the mixture under the surface of the mixture so as to minimize bubble formation.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 067728/0327 →
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2024
From: DEERFIELD MGMT, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 066725/0043 →
SECURITY INTEREST Recorded Feb 10, 2022
From: NEOS THERAPEUTICS, LP
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 058977/0069 →
RELEASE OF SECURITY INTEREST Recorded Jan 28, 2022
From: DEERFIELD MGMT, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 058814/0437 →
SECURITY INTEREST Recorded Oct 7, 2019
From: NEOS THERAPEUTICS, LP
To: DEERFIELD MGMT, L.P., AS COLLATERAL AGENT
Reel/Frame 050638/0952 →
SECURITY INTEREST Recorded Oct 2, 2019
From: NEOS THERAPEUTICS, LP
To: ENCINA BUSINESS CREDIT, LLC, AS AGENT
Reel/Frame 050606/0096 →
SECURITY INTEREST Recorded Jun 15, 2016
From: NEOS THERAPEUTICS, LP
To: DEERFIELD MGMT, L.P., AS COLLATERAL AGENT
Reel/Frame 038918/0965 →
RELEASE OF SECURITY INTEREST Recorded May 17, 2016
From: FROST BANK (SUCCESSOR-BY-MERGER TO SUMMIT BANK, N.A.)
To: NEOS THERAPEUTICS, LP (FORMERLY KNOWN AS PFAB LP)
Reel/Frame 038617/0158 →
CHANGE OF NAME Recorded Aug 7, 2007
From: PFAB LP
To: NEOS THERAPEUTICS, LP
Reel/Frame 019661/0584 →
SECURITY AGREEMENT Recorded Aug 3, 2005
From: PFAB LP
To: SUMMIT BANK, N.A.
Reel/Frame 016350/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2005
From: TENGLER, MARK; TASKEY, PAUL; LOCKHART, DANIEL; MCMAHEN, RUSS
To: PFAB, LP
Reel/Frame 016304/0189 →
Continuity (1)
Related Publication 20060193877A1 · Aug 31, 2006